PACIRA BIOSCIENCES, INC. Amortization of Debt Issuance Costs
PACIRA BIOSCIENCES, INC. (PCRX) reported Amortization of Debt Issuance Costs of $521.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. amortization of debt issuance costs for the quarter ending 2026-06-30 was $521.00K, a 38.63% decline year-over-year.
- PACIRA BIOSCIENCES, INC. amortization of debt issuance costs for the quarter ending 2026-03-31 was $521.00K, a 38.34% decline year-over-year.
- PACIRA BIOSCIENCES, INC. amortization of debt issuance costs for the quarter ending 2025-12-31 was $520.00K, a 38.53% decline year-over-year.
- PACIRA BIOSCIENCES, INC. amortization of debt issuance costs for the quarter ending 2025-09-30 was $626.00K, a 25.48% decline year-over-year.
- PACIRA BIOSCIENCES, INC. amortization of debt issuance costs for fiscal 2025 was $2.84M, a 9.27% decline from fiscal 2024.
- PACIRA BIOSCIENCES, INC. amortization of debt issuance costs for fiscal 2024 was $3.13M, a 4.47% increase from fiscal 2023.
- PACIRA BIOSCIENCES, INC. amortization of debt issuance costs for fiscal 2023 was $3.00M, a 31.91% decline from fiscal 2022.
- PACIRA BIOSCIENCES, INC. amortization of debt issuance costs for fiscal 2022 was $4.40M, a 59.77% increase from fiscal 2021.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $521.00K 10-Q · filed 2026-08-04 | $1.04M 10-Q · filed 2026-08-04 | $1.56M derived: sum of 3 quarters · filed 2026-08-04 | $2.19M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $521.00K 10-Q · filed 2026-04-30 | $1.04M derived: sum of 2 quarters · filed 2026-04-30 | $1.67M derived: sum of 3 quarters · filed 2026-04-30 | $2.52M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $520.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.15M derived: sum of 2 quarters · filed 2026-02-26 | $2.00M derived: sum of 3 quarters · filed 2026-08-04 | $2.84M 10-K · filed 2026-02-26 |
| 2025-09-30 | $626.00K 10-Q · filed 2025-11-06 | $1.48M derived: sum of 2 quarters · filed 2026-08-04 | $2.32M 10-Q · filed 2025-11-06 | $3.17M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $849.00K 10-Q · filed 2026-08-04 | $1.69M 10-Q · filed 2026-08-04 | $2.54M derived: sum of 3 quarters · filed 2026-08-04 | $3.38M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $845.00K 10-Q · filed 2026-04-30 | $1.69M derived: sum of 2 quarters · filed 2026-04-30 | $2.53M derived: sum of 3 quarters · filed 2026-04-30 | $3.29M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $846.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.69M derived: sum of 2 quarters · filed 2026-02-26 | $2.45M derived: sum of 3 quarters · filed 2026-02-26 | $3.13M 10-K · filed 2026-02-26 |
| 2024-09-30 | $840.00K 10-Q · filed 2025-11-06 | $1.60M derived: sum of 2 quarters · filed 2025-11-06 | $2.28M 10-Q · filed 2025-11-06 | $2.97M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $763.00K 10-Q · filed 2025-08-05 | $1.44M 10-Q · filed 2025-08-05 | $2.13M derived: sum of 3 quarters · filed 2026-02-26 | $2.81M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $681.00K 10-Q · filed 2025-05-08 | $1.37M derived: sum of 2 quarters · filed 2026-02-26 | $2.05M derived: sum of 3 quarters · filed 2026-02-26 | $2.74M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $685.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.37M derived: sum of 2 quarters · filed 2026-02-26 | $2.06M derived: sum of 3 quarters · filed 2026-02-26 | $3.00M 10-K · filed 2026-02-26 |
| 2023-09-30 | $683.00K 10-Q · filed 2024-11-06 | $1.37M derived: sum of 2 quarters · filed 2024-11-06 | $2.31M 10-Q · filed 2024-11-06 | $3.75M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $691.00K 10-Q · filed 2024-07-30 | $1.63M 10-Q · filed 2024-07-30 | $3.07M derived: sum of 3 quarters · filed 2025-02-27 | $3.98M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $937.00K 10-Q · filed 2024-05-07 | $2.38M derived: sum of 2 quarters · filed 2025-02-27 | $3.28M derived: sum of 3 quarters · filed 2025-02-27 | $4.16M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.35M derived: sum of 2 quarters · filed 2025-02-27 | $3.22M derived: sum of 3 quarters · filed 2025-02-27 | $4.40M 10-K · filed 2025-02-27 |
| 2022-09-30 | $903.00K 10-Q · filed 2023-11-02 | $1.78M derived: sum of 2 quarters · filed 2023-11-02 | $2.96M 10-Q · filed 2023-11-02 | $3.73M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $874.00K 10-Q · filed 2023-08-02 | $2.05M 10-Q · filed 2023-08-02 | $2.83M derived: sum of 3 quarters · filed 2024-02-29 | $3.50M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $1.18M 10-Q · filed 2023-05-03 | $1.96M derived: sum of 2 quarters · filed 2024-02-29 | $2.62M derived: sum of 3 quarters · filed 2024-02-29 | $3.28M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $778.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.44M derived: sum of 2 quarters · filed 2024-02-29 | $2.10M derived: sum of 3 quarters · filed 2024-02-29 | $2.75M 10-K · filed 2024-02-29 |
| 2021-09-30 | $666.00K 10-Q · filed 2022-11-03 | $1.32M derived: sum of 2 quarters · filed 2022-11-03 | $1.98M 10-Q · filed 2022-11-03 | $2.62M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $659.00K 10-Q · filed 2022-08-03 | $1.31M 10-Q · filed 2022-08-03 | $1.95M derived: sum of 3 quarters · filed 2023-02-28 | $2.58M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $651.00K 10-Q · filed 2022-05-04 | $1.29M derived: sum of 2 quarters · filed 2023-02-28 | $1.92M derived: sum of 3 quarters · filed 2023-02-28 | $2.37M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $644.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.27M derived: sum of 2 quarters · filed 2023-02-28 | $1.72M derived: sum of 3 quarters · filed 2023-02-28 | $2.16M 10-K · filed 2023-02-28 |
| 2020-09-30 | $629.00K 10-Q · filed 2021-11-03 | $1.07M derived: sum of 2 quarters · filed 2021-11-03 | $1.51M 10-Q · filed 2021-11-03 | $1.95M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $444.00K 10-Q · filed 2021-08-03 | $883.00K 10-Q · filed 2021-08-03 | $1.32M derived: sum of 3 quarters · filed 2022-02-28 | $1.75M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $439.00K 10-Q · filed 2021-05-04 | $873.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.30M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $434.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $863.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.71M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $429.00K 10-Q · filed 2020-10-30 | $1.27M 10-Q · filed 2020-10-30 | ||
| 2018-12-31 | $1.63M 10-K · filed 2021-03-01 | |||
| 2017-03-31 | $201.00K 10-Q · filed 2017-05-04 | |||
| 2016-03-31 | $153.00K 10-Q · filed 2017-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |